-
New epilepsy drug dp-vpa jointly developed by Enhua pharmaceutical and d-pharm in Israel has entered the phase III clinical trial
Time of Update: 2020-04-03
Jiangsu Enhua Pharmaceutical Co., Ltd said in the morning of February 14 that the dp-vpa innovative drug jointly developed by Enhua pharmaceutical and Israeli d-pharm company is currently in the phase
-
Inventory (1): number of clinical approval of drugs in the first half of 2013-2015
Time of Update: 2020-04-03
In the environment of the growth of biological drugs and the shrinking of the registration of imported drugs, what is the situation of drug approval in China? According to insight database statistics,
-
Temozolomide, a class 3.3 new antitumor drug of Hengrui medicine, has obtained clinical approval
Time of Update: 2020-04-03
Temozolomide for injection of Hengrui medicine has completed the clinical examination and approval, and is in the state of pending certification It is worth noting that the temozolomide for injection
-
"New Viagra" of Tianfang pharmaceutical needs at least 5 years to be listed
Time of Update: 2020-04-03
On July 10, a news that "tpn729ma, a new drug of Tianfang pharmaceutical industry absorbed and merged by China pharmaceutical, has been prepared and certified by the State Food and drug administration
-
Continuous haze causes pharmaceutical companies to speed up new drug research and development
Time of Update: 2020-04-03
The continuous haze in most areas of China is having a serious impact on public health Recently, the author learned from many pharmaceutical companies that respiratory related therapeutic drugs contin
-
Application for clinical application of two new drugs of class 1.1 in Kelun pharmaceutical
Time of Update: 2020-04-03
According to the information from the State Food and Drug Administration on April 15, the application of ceftoren sodium phosphate for injection and ceftoren sodium for injection by Kelun Pharmaceutic
-
Haizheng Pharmaceutical Co., Ltd. applied for clinical application of class 3.1 chemical drug API for sirolimus and was accepted
Time of Update: 2020-04-03
Recently, according to the website of the State Food and Drug Administration (CFDA), the 3.1 chemical raw material drug tirocimose and preparation injection tirocimose applied for clinical application
-
Lupatadine fumarate tablets, a new class 3.1 antiallergic drug, was approved for production
Time of Update: 2020-04-03
According to the information on the website of the State Food and Drug Administration (CFDA), the state of lupatadine fumarate, a new class 3.1 drug under development by Hisilicon, has been changed to
-
The production of "loratrak hydrochloride", a new anti-tumor drug of Kangchen Pharmaceutical Co., Ltd., has been declared
Time of Update: 2020-04-03
Loratrek hydrochloride for injection, a national first-class anti-cancer drug developed by Kangchen Pharmaceutical Development Co., Ltd., is a non classical structure of folic acid thymidylate synthet
-
Phase IV clinical application of Yikai tablet (pancreatic kininogenase enteric coated tablet), a key product of Qianhong pharmaceutical
Time of Update: 2020-04-03
Haitao, marketing director of Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd., said in the investigation that the company's main product, Yikai tablet (Pancreatic Kallidinogenase enteric coate
-
HongRi pharmaceutical company's first imitative drug for the treatment of venous thromboembolism
Time of Update: 2020-04-03
PTS injection, a new anticancer drug of HongRi pharmaceutical, is still in the stage of production approval and is progressing smoothly We expect that it will be approved and marketed in 2014 The sulf
-
Application for production of letrozole, a 6-class imitative drug of Zhendong pharmaceutical in the treatment of breast cancer
Time of Update: 2020-04-03
The application of letrozole, a 6-class generic drug declared by Zhendong pharmaceutical, has been accepted Letrozole mainly treats breast cancer The company has declared its API and tablet, mainly to
-
Category list of drug review and consultation meeting in August 2015
Time of Update: 2020-04-03
From August 19 to 21, 2015, the drug review center organized the 7th drug review consultation meeting in Guangxi building, Beijing 101 experts were invited to attend the meeting At the same time, 13 a
-
31 people have been vaccinated with HIV vaccine in clinical trials in China
Time of Update: 2020-04-03
31 years after the discovery of AIDS, the first drug for the prevention of uninfected people was approved by the US FDA on July 16 this year At the 19th World AIDS conference, which ended 10 days late
-
Enhua pharmaceutical heavy new drug Remifentanil Hydrochloride for Injection approval completed
Time of Update: 2020-04-03
According to the information on the website of CFDA on October 13, the review status of remifentanil hydrochloride for injection, a heavy new drug of Enhua Pharmaceutical Co., Ltd., was changed to "ap
-
Minutes of overseas authorized conference call of Hengrui pharmaceutical PD-1
Time of Update: 2020-04-03
The company has signed an agreement with Incyte company, the main content of which is: within 30 days after receiving the receipt from Hengrui, Incyte company of the United States will pay the down pa
-
Kangyuan pharmaceutical won the national science and technology progress award again
Time of Update: 2020-04-03
On January 8, good news came from the 2015 National Science and technology award conference: Kangyuan Pharmaceutical Co., Ltd led to complete the project of "establishment and application of quality s
-
Hepatitis C treatment in China is facing severe challenges. New drugs may change the status quo
Time of Update: 2020-04-03
Recently, Roche and Geli Biotechnology (Hangzhou) Co., Ltd (hereinafter referred to as "Geli") jointly announced that they would cooperate in the R & D and production of new Roche hepatitis C drug da
-
Jingxin Pharmaceutical Co., Ltd. and xinlitai entered the three in one review on the same day
Time of Update: 2020-04-03
Levetiracetam is a pyrrolidone derivative Because of its high therapeutic index, mild adverse reactions and good tolerance, it is the most widely used new antiepileptic drug In China, only the origina
-
Sang Guowei: Strive to independently create 30 innovative drugs during the "Twelfth Five-Year Plan"
Time of Update: 2020-04-03
Sang Guowei, vice chairman of the Standing Committee of the Eleventh National People's Congress, said at the fourth China (Taizhou) International Pharmaceutical exposition that the goal of the "12th F
